Stephens & Co. Maintains Overweight on 10x Genomics, Raises Price Target to $65

Benzinga Newsdesk www.benzinga.com Positive 53.4%

Neg 0% Neu 0% Pos 53.4%

Stephens & Co. analyst Mason Carrico maintains 10x Genomics (NASDAQ:TXG) with a Overweight and raises the price target from $50 to $65.